观点网讯:4月21日,复星医药发布关于增持控股子公司股权的提示性公告。公告显示,2025年4月11日至4月17日期间,复星医药控股子公司复星医药产业与上海善梧、无锡通善、舟山果运及Henlink分别签订转让协议,复星医药产业拟以港币24.60元/股的价格受让该等卖方持有的合计21,034,313股复宏汉霖非上市股份(约占截至本公告日期复宏汉霖股份总数的3.87%),转让价款共计港币517,444,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.